SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the U.S. sucralfate market was valued at US$ 296.2 million in 2017, and is projected to exhibit a CAGR of 3.1% over the forecast period (2018–2026).
Key Trends and Analysis of the U.S. Sucralfate Market:
Key trends in market are increasing prevalence of gastrointestinal disorders and H. pylori-associated infections and increasing research and development activities by market players.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2975
Increasing number of people affected by H. pylori infection is expected to increase the risk of gastric and duodenal ulcers, which in turn is expected to augment growth of the U.S. sucralfate market. According to the data published by International Foundation for Gastrointestinal Disorders in 2017, the prevalence of gastroesophageal reflux disease in U.S. was around 18 to 28% of the total population. Similarly, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2014, around 30 to 40% of people in the U.S. suffer from H. pylori infection, which increases the risk of duodenal and gastric ulcer development.
Ask for a Discount Now @ https://www.coherentmarketinsights.com/insight/request-discount/2975
Furthermore, increasing research and development activities is expected to drive the U.S. sucralfate market growth. For instance the University of Texas is conducting a clinical phase II study on sucralfate to improve oral intake in children with infectious oral ulcers. The study is expected to be completed by June 2019.
However, the availability of other over-the-counter products such as H2 antagonists, proton pump inhibitors, and antacids to reduce stomach acid for preventing heart burn and gastritis are major factors hindering the market growth. The alternative OTC/prescription medications include Tums (Calcium carbonate), Zantac 75 (ranitidine), Pepcid (Famotidine), Prevacid (lansoprazole), Prilosec (omeprazole), Protonix (pantoprazole), and Pepto-Bismol (bismuth subsalicylate).
Buy this report (Single Users License) @ https://www.coherentmarketinsights.com/insight/buy-now/2975
Key Market Takeaways:
- The U.S. sucralfate market is expected to exhibit a CAGR of 3.1% during the forecast period (2018–2026), owing to increasing prevalence of gastrointestinal disorders and H. pylori-associated infections and increasing research and development activities by market players. According to the American Broncho Esophagological Association report in April 2018, use of sucralfate along with honey aids in treatment of esophageal injury in infants and children. Esophageal injury in infants and children are associated with consumption of Button Batteries (BB), small disc-shaped batteries commonly found in toys. Use of sucralfate with honey can help in mitigation of the button batteries and allows symptomatic relief from esophageal injury.
- Key players in the market are focused on acquisition and collaboration strategies to enhance their research and development activities, which in turn is expected to propel the market growth over the forecast period. For instance, in 2014, Aptalis Pharma Inc., a specialty pharmaceutical company and manufacturer of Carafate, was acquired by Forest Laboratories, Inc., a fully integrated, specialty pharmaceutical company. Forest agreed to acquire Aptalis from TPG, the global private investment firm, for US$ 2.9 billion in cash.
- Key players operating in the U.S. sucralfate market include Teva Pharmaceutical Industries Ltd., Allergan plc, Vertice Pharma LLC, and Pharmaceutical Associates Inc.
To know the latest trends and insights prevalent in this market, click the link below:
U.S. Sucralfate Market, By Formulation:
- Unit Dose Cup
U.S. Sucralfate Market, By Indication:
- Gastric Ulcers
- Duodenal Ulcers
- Gastro Esophageal Reflux Disease (GERD)
U.S. Sucralfate Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
U.S. Sucralfate Market, By State:
- New York
- Company Profiles